We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-29.19%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$449M
Cap. Flow
+$71M
Cap. Flow %
12.79%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$95M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$12.9M
2
MTCR
Metacrine, Inc. Common Stock
MTCR
+$10.5M
3
AKRO
Akero Therapeutics
AKRO
+$646K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$208M 37.55%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$117M 21.05%
2,740,411
-322,783
-11% -$12.9M
VTYX
3
DELISTED
Ventyx Biosciences
VTYX
$99.5M 17.93%
+5,011,536
New +$95M
AKRO
4
DELISTED
Akero Therapeutics
AKRO
$45.9M 8.28%
2,171,664
-29,114
-1% -$646K
PHVS icon
5
Pharvaris
PHVS
$2.48B
$33.1M 5.97%
2,303,310
– –
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$23.8M 4.29%
2,759,791
– –
ELEV
7
DELISTED
Elevation Oncology
ELEV
$15.7M 2.83%
2,608,167
– –
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$10.5M 1.9%
3,673,374
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$1.09M 0.2%
161,897
– –
MTCR
10
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-3,059,123
Closed -$10.5M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q4 2021 Portfolio in Review

As of Q4 2021, venBio Partners held 10 positions worth $555M, down 45% from $1B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $71M of net new capital in Q4 2021, opening 1 new position. Its largest new stake was Ventyx Biosciences: 5,011,536 shares worth $99.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Harmony Biosciences, an estimated $12.9M trimmed.

  • venBio Partners's largest Q4 2021 buy was Ventyx Biosciences: 5,011,536 shares worth $99.5M.
  • venBio Partners's biggest Q4 2021 reduction was Harmony Biosciences, cutting an estimated $12.9M.
  • venBio Partners fully exited Metacrine, Inc. Common Stock in Q4 2021, selling an estimated $10.5M.
  • venBio Partners's ten largest holdings make up 100% of its $555M portfolio in Q4 2021.
  • venBio Partners opened 1 new position and closed 1 in Q4 2021.
  • venBio Partners's portfolio value fell 45% quarter-over-quarter to $555M.

Based on venBio Partners's 13F filing for Q4 2021, filed 14 Feb 2022.